Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => 7期肝癌的诊断和治疗 => 病毒性肝炎 => 核苷和核苷酸类药物治疗慢性乙型肝炎停药后复发并进展为肝衰竭患者的临床特征.
Clinical features of HBV-related liver failure associated with recurrence after withdrawal of nucleos(t)ide analogues and influencing factors for prognosis
文章发布日期:2018年06月07日  来源:  作者:李孝楼,卓海燕,刘志强,等  点击次数:752次  下载次数:136次
Adjust font size:Small regular big

【Abstract】:Objective To investigate the clinical features of chronic hepatitis B (CHB) patients progressing to liver failure due to recurrence after withdrawal of nucleos(t)ide analogues and influencing factors for prognosis. Methods A retrospective analysis was performed for the clinical data of 40 patients with liver failure due to recurrence after drug withdrawal who were admitted to Mengchao Hepatobiliary Hospital of Fujian Medical University from January 2014 to December 2017, including general information, antiviral therapy, and biochemical and virological data. According to the treatment outcome at week 12, the patients were divided into survival group with 18 patients and death group with 22 patients, and clinical features were compared between the two groups. The t-test was used for comparison of normally distributed continuous data between groups, and the Mann-Whitney U test was used for comparison of continuous data with skewed distribution between groups. The chi-square test was used for comparison of categorical data between groups. The logistic regression analysis was performed to identify the influencing factors for recurrence and progression to liver failure after drug withdrawal. Results There were no significant differences between the death group and the survival group in median time of antiviral therapy and time from drug withdrawal to recurrence (P>0.05), and the death group had a significantly higher proportion of patients with liver cirrhosis than the survival group (81.8% vs 27.8%, χ2=11.831, P=0.001). Compared with the death group, the survival group had significantly higher levels of albumin (t=2.302), gamma-glutamyl transpeptidase (Z=-3.671), and cholinesterase (Z=-2.134) and significantly lower total bilirubin (Z=-4.241), prothrombin time (t=-2.727), international normalized ratio (t=-2.343), and Model for End-Stage Liver Disease score (t=-3.909) (all P<0.05). There was a significant difference in acute-on-chronic liver failure (ACLF) grade between the two groups (χ2=18.425, P<0.001). The logistic regression analysis showed that ACLF grade (odds ratio [OR]=9.865, 95% confidence interval [CI]: 1.455-67.370, P=0.020) and liver cirrhosis (OR=9.988, 95%CI: 2.048-48.709, P=0.004) were independent risk factors for the prognosis of liver failure due to recurrence after drug withdrawal. Conclusion Liver failure due to recurrence after drug withdrawal has a high mortality rate, and its prognosis is not associated with antiviral regimen, course of treatment, or virological parameters. Patients with liver cirrhosis and a higher liver failure grade tend to have poorer prognosis. Patients with liver cirrhosis have a high risk after drug withdrawal and should take the medicine for a long time or even for the whole life.
【Key words】:hepatitis B, chronic; liver failure; antiviral agents; recurrence; risk factors

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号